Both Kazia Therapeutics Limited (NASDAQ:KZIA) and Trillium Therapeutics Inc. (NASDAQ:TRIL) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kazia Therapeutics Limited||N/A||0.00||N/A||-0.89||0.00|
|Trillium Therapeutics Inc.||N/A||0.00||N/A||-2.55||0.00|
Demonstrates Kazia Therapeutics Limited and Trillium Therapeutics Inc. earnings per share (EPS), top-line revenue and valuation.
Table 2 provides the net margins, return on equity and return on assets of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Kazia Therapeutics Limited||0.00%||0%||0%|
|Trillium Therapeutics Inc.||0.00%||0%||0%|
In next table is delivered Kazia Therapeutics Limited and Trillium Therapeutics Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Kazia Therapeutics Limited||0||0||0||0.00|
|Trillium Therapeutics Inc.||0||1||1||2.50|
Meanwhile, Trillium Therapeutics Inc.’s average price target is $2.5, while its potential upside is 331.03%.
Insider and Institutional Ownership
Roughly 2.5% of Kazia Therapeutics Limited shares are owned by institutional investors while 39.41% of Trillium Therapeutics Inc. are owned by institutional investors. About 28.8% of Kazia Therapeutics Limited’s share are owned by insiders. On the other hand, insiders owned about 0.37% of Trillium Therapeutics Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Kazia Therapeutics Limited||11.59%||13.84%||47.51%||9.07%||-11.9%||58.44%|
|Trillium Therapeutics Inc.||-5.61%||-61.62%||-75.2%||-88.07%||-90.46%||-59.53%|
For the past year Kazia Therapeutics Limited had bullish trend while Trillium Therapeutics Inc. had bearish trend.
On 3 of the 4 factors Kazia Therapeutics Limited beats Trillium Therapeutics Inc.
Kazia Therapeutics Limited, a biotechnology company, develops anti-cancer drugs. It has three technologies, which include phosphoinositide 3-kinase inhibitors, superbenzopyran, and anti-tropomyosin. The company is developing GDC-0084, a novel targeted therapy that has completed Phase I clinical trial for the treatment of glioblastoma; Cantrixil, which is in Phase I clinical trials to treat ovarian cancer; and Trilexium, a novel therapy that is in early stage pre-clinical development for the treatment of various cancer types. It has collaboration agreement with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, and the University of Boston. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.